Pneumococcal surface protein A (PspA) is effective at eliciting T cell-mediated responses during invasive pneumococcal disease in adults
- PMID: 16879247
- PMCID: PMC1809691
- DOI: 10.1111/j.1365-2249.2006.03148.x
Pneumococcal surface protein A (PspA) is effective at eliciting T cell-mediated responses during invasive pneumococcal disease in adults
Abstract
Humoral immune response is essential for protection against invasive pneumococcal disease and this property is the basis of the polysaccharide-based anti-pneumococcal vaccines. Pneumococcal surface protein A (PspA), a cell-wall-associated surface protein, is a promising component for the next generation of pneumococcal vaccines. This PspA antigen has been shown to stimulate an antibody-based immunity. In the present study, we evaluated the capacity of PspA to stimulate CD4+ T cells which are needed for the correct development of a B cell based immune response in humans. Cellular immunity to PspA was evaluated by whole-blood culture with different pneumococcal antigens, followed by flow cytometric detection of activated CD4+CD25+ T cells. T cell-mediated immune responses to recombinant PspA proteins were assessed in acute-phase and convalescent blood from adults with invasive pneumococcal disease and in blood from healthy subjects. All cases had detectable antibodies against PspA on admission. We found that invasive pneumococcal disease induced transient T cell depletion but adaptive immune responses strengthened markedly during convalescence. The increased production of both interleukin (IL)-10 and interferon (IFN)-gamma during convalescence suggests that these cytokines may be involved in modulating antibody-based immunity to pneumococcal disease. We demonstrated that PspA is efficient at eliciting T cell immune responses and antibodies to PspA. This study broadens the applicability of recombinant PspA as potent pneumococcal antigen for vaccination against S. pneumoniae.
Figures



Similar articles
-
Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice.Vaccine. 2011 Aug 5;29(34):5731-9. doi: 10.1016/j.vaccine.2011.05.095. Epub 2011 Jun 13. Vaccine. 2011. PMID: 21696869
-
Enhanced protective immunity against pneumococcal infection with PspA DNA and protein.Vaccine. 2006 Jul 17;24(29-30):5755-61. doi: 10.1016/j.vaccine.2006.04.046. Epub 2006 May 4. Vaccine. 2006. PMID: 16759765
-
Antibodies to the pneumococcal surface protein A, PspA, can be produced in splenectomized and can protect splenectomized mice from infection with Streptococcus pneumoniae.Vaccine. 2005 Jul 21;23(33):4257-62. doi: 10.1016/j.vaccine.2005.03.039. Vaccine. 2005. PMID: 16005736
-
Pneumococcal conjugate vaccine for young children.Manag Care. 2000 Sep;9(9):49-52, 54, 56-7 passim. Manag Care. 2000. PMID: 11116663 Review.
-
[Pneumococcal surface protein A and new approaches for pneumococcal vaccine development].Zh Mikrobiol Epidemiol Immunobiol. 2011 Nov-Dec;(6):107-13. Zh Mikrobiol Epidemiol Immunobiol. 2011. PMID: 22308742 Review. Russian.
Cited by
-
c-di-GMP is an effective immunomodulator and vaccine adjuvant against pneumococcal infection.Vaccine. 2008 Aug 26;26(36):4676-85. doi: 10.1016/j.vaccine.2008.06.099. Epub 2008 Jul 18. Vaccine. 2008. PMID: 18640167 Free PMC article.
-
Prediction and Validation of Immunogenic Domains of Pneumococcal Proteins Recognized by Human CD4+ T Cells.Infect Immun. 2019 May 21;87(6):e00098-19. doi: 10.1128/IAI.00098-19. Print 2019 Jun. Infect Immun. 2019. PMID: 30910792 Free PMC article.
-
Antibody-independent, CD4+ T-cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins.Infect Immun. 2007 Nov;75(11):5460-4. doi: 10.1128/IAI.00773-07. Epub 2007 Aug 13. Infect Immun. 2007. PMID: 17698570 Free PMC article.
-
Establishment of an ELISpot Assay to Detect Cellular Immunity against S. pneumoniae in Vaccinated Kidney Transplant Recipients.Vaccines (Basel). 2021 Dec 6;9(12):1438. doi: 10.3390/vaccines9121438. Vaccines (Basel). 2021. PMID: 34960184 Free PMC article.
-
Asthma and antibodies to pneumococcal virulence proteins.Infection. 2013 Oct;41(5):927-34. doi: 10.1007/s15010-013-0482-3. Epub 2013 Jun 8. Infection. 2013. PMID: 23749296 Free PMC article.
References
-
- Black SB, Shinefield H, Baxter R, et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J. 2004;23:485–9. - PubMed
-
- Eskola J. Immunogenicity of pneumococcal conjugate vaccines. Pediatr Infect Dis J. 2000;19:388–93. - PubMed
-
- Jackson LA, Neuzil KM, Yu O, et al. Vaccine safety datalink. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med. 2003;348:1747–55. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials